PROTAC eEF2K degrader-2
PROTAC eEF2K degrader-2 is a CRBN-recruiting eEF2K degrader (DC50 values of 0.88 and 0.67 μM in MDA-MB-231 and HCC1806 TNBC cells, respectively). PROTAC eEF2K degrader-2 binds to the thalidomide (Thalidomide) (HY-14658) binding domain of CRBN , forming an eEF2K-CRBN ternary complex, promoting eEF2K polyubiquitination and proteasomal degradation, and inhibiting eEF2 phosphorylation. PROTAC eEF2K degrader-2 induces apoptosis and inhibits EMT, cell migration, proliferation, colony formation, and TNBC organoid growth. PROTAC eEF2K degrader-2 can be used for research on triple-negative breast cancer.
(Pink: CaMK III/eEF-2K ligand (HY-188621); Blue: Cereblon ligand (HY-10984); Black: linker).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3070364-13-2
- Formel: C39H47N7O9
- Molecular Weight:757.83
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CaMK III/eEF-2K 0.88 μM (DC50, MDA-MB-231 cells) |
CaMK III/eEF-2K 0.67 μM (DC50, HCC1806 TNBC cells) |
Cereblon |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
13.98 μM
|
Cytotoxicity against human MDA-MB-231 TNBC cells assessed by CCK-8 viability assay.
Cytotoxicity against human MDA-MB-231 TNBC cells assessed by CCK-8 viability assay.
|
41589674 |
| HCC1806 | IC50 |
8.70 μM
|
Cytotoxicity against human HCC1806 TNBC cells assessed by CCK-8 viability assay.
Cytotoxicity against human HCC1806 TNBC cells assessed by CCK-8 viability assay.
|
41589674 |
| BT-549 | IC50 |
13.25 μM
|
Cytotoxicity against human BT549 TNBC cells assessed by CCK-8 viability assay.
Cytotoxicity against human BT549 TNBC cells assessed by CCK-8 viability assay.
|
41589674 |
| MDA-MB-231 | DC50 |
0.88 μM
|
DC50 for eEF2K degradation in human MDA-MB-231 TNBC cells assessed by Western blot after 48 hrs.
DC50 for eEF2K degradation in human MDA-MB-231 TNBC cells assessed by Western blot after 48 hrs.
|
41589674 |
| HCC1806 | DC50 |
0.67 μM
|
DC50 for eEF2K degradation in human HCC1806 TNBC cells assessed by Western blot.
DC50 for eEF2K degradation in human HCC1806 TNBC cells assessed by Western blot.
|
41589674 |
| MCF7 | IC50 |
26.28 μM
|
Cytotoxicity against human MCF-7 breast cancer cells assessed as cell viability IC50.
Cytotoxicity against human MCF-7 breast cancer cells assessed as cell viability IC50.
|
41589674 |
| T47D | IC50 |
29.7 μM
|
Cytotoxicity against human T47D breast cancer cells assessed as cell viability IC50.
Cytotoxicity against human T47D breast cancer cells assessed as cell viability IC50.
|
41589674 |
| SK-BR-3 | IC50 |
30.01 μM
|
Cytotoxicity against human SK-BR-3 breast cancer cells assessed as cell viability IC50.
Cytotoxicity against human SK-BR-3 breast cancer cells assessed as cell viability IC50.
|
41589674 |
| MCF-10A | IC50 |
> 100 μM
|
Cytotoxicity against non-tumorigenic human MCF-10A cells assessed as cell viability IC50 greater than 100 μM.
Cytotoxicity against non-tumorigenic human MCF-10A cells assessed as cell viability IC50 greater than 100 μM.
|
41589674 |
In Vitro
PROTAC eEF2K degrader-2 (10-20 μM; 2 days) reduces colony formation in MDA-MB-231, HCC1806, and BT549 TNBC cells[1].
PROTAC eEF2K degrader-2 (10-20 μM; 48 h) inhibits the migration of MDA-MB-231, HCC1806, and BT549 TNBC cells[1].
PROTAC eEF2K degrader-2 (2.50-10.00 μM) inhibits the expression of EMT markers in MDA-MB-231, HCC1806, and BT549 TNBC cells[1].
PROTAC eEF2K degrader-2 (2.50-10.00 μM) modulates apoptosis-regulating factors in MDA-MB-231, HCC1806, and BT549 TNBC cells, shifting them toward apoptosis[1].
PROTAC eEF2K degrader-2 (10-20 μM) activity depends on eEF2K expression in MDA-MB-231 and HCC1806 TNBC cells[1].
PROTAC eEF2K degrader-2 (2.5-20 μM) inhibits TNBC organoids[1].
PROTAC eEF2K degrader-2 (2.50-10.00 µM) induces concentration-dependent eEF2K degradation in MDA-MB-231 and HCC1806 TNBC cells[1].
PROTAC eEF2K degrader-2 exhibits stronger effects in TNBC cell lines MDA-MB-231 and HCC1806 (IC50 of 13.98 and 8.70 µM, respectively) than in non-TNBC breast cancer cell lines, with an IC50 > 100 µM in MCF-10A cells[1].
PROTAC eEF2K degrader-2 inhibits colony formation in MDA-MB-231 and HCC1806 TNBC cells, and this effect is partially reversed by co-exposure to MG132 (HY-13259) or Pevonedistat (MLN4924) (HY-70062)[1].
PROTAC eEF2K degrader-2 (10 μM; 3-48 h) induces sustained time-dependent eEF2K degradation in MDA-MB-231 and HCC1806 TNBC cells[1].
PROTAC eEF2K degrader-2 (5-20 μM) depletes eEF2K protein in MDA-MB-231 and HCC1806 TNBC cells without reducing eEF2K mRNA[1].
PROTAC eEF2K degrader-2 (2.50-10.00 μM) inhibits eEF2K signaling in MDA-MB-231 and HCC1806 TNBC cells while preserving total eEF2[1].
PROTAC eEF2K degrader-2 requires the proteasome and neddylation pathways to degrade eEF2K in MDA-MB-231 and HCC1806 TNBC cells[1].
PROTAC eEF2K degrader-2 (10 μM; overnight) directly binds eEF2K in MDA-MB-231 and HCC1806 TNBC cells, increasing thermal stability by 1.23°C and 3.94°C, respectively[1].
PROTAC eEF2K degrader-2 (10 μM; 20 μg/mL Cycloheximide (CHX) (HY-12320); 0-12 h) accelerates the turnover of eEF2K in MDA-MB-231 and HCC1806 TNBC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, HCC1806, BT549, MCF-7, T47D, SK-BR-3, and MCF-10A cells
-
Concentration:13.98 μM (MDA-MB-231 IC50); 8.70 μM (HCC1806 IC50); 13.25 μM (BT549 IC50); 10 and 20 μM (time-course)
-
Incubation Time:1, 2, and 3 days (time-course proliferation)
-
Result:IC50 values were 13.98 μM in MDA-MB-231, 8.70 μM in HCC1806, and 13.25 μM in BT549 cells.
Proliferation was suppressed in ER-positive MCF-7 and T47D cells and HER2-positive SK-BR-3 cells, with minimal cytotoxicity toward normal MCF-10A cells.
Relative cell number was suppressed in a time- and dose-dependent manner in MDA-MB-231, HCC1806, and BT549 cells.
-
Cell Line:MDA-MB-231, HCC1806, and BT549 cells
-
Concentration:10 and 20 μM
-
Incubation Time:2 days
-
Result:Colony size and colony number were reduced in MDA-MB-231, HCC1806, and BT549 cells compared with control cells.
-
Cell Line:MDA-MB-231, HCC1806, and BT549 cells
-
Concentration:10 and 20 μM
-
Incubation Time:48 h
-
Result:Migration was inhibited, with reduced scratch closure compared with controls in MDA-MB-231, HCC1806, and BT549 cells.
-
Cell Line:MDA-MB-231 and HCC1806 cells
-
Concentration:0.31, 0.62, 1.25, 2.50, 5.00, and 10.00 μM; 10 μM (48 h degradation-rate determination)
-
Incubation Time:48 h (degradation-rate determination)
-
Result:Concentration-dependent eEF2K depletion occurred.
At 10 μM, 93.32% eEF2K degradation was achieved in MDA-MB-231 cells after 48 h.
DC50 values were 0.88 μM and 0.67 μM in the two cell-based degradation assays.
-
Cell Line:MDA-MB-231 and HCC1806 cells
-
Concentration:10 μM
-
Incubation Time:3, 6, 9, 12, 24, and 48 h; washout at 3, 6, 12, 24, and 48 h after removal
-
Result:Progressive time-dependent eEF2K depletion occurred.
After washout, eEF2K protein levels remained below 50% of baseline at 48 h after removal.
In Vivo
PROTAC eEF2K degrader-2 (2.5 mg/kg; intraperitoneal injection) reduces the MDA-MB-231 xenograft tumor burden in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 4 weeks old)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; every other day; 14 days
-
Result:Tumor growth was suppressed compared with vehicle at 10 mg/kg and 20 mg/kg.
Xenograft tumors showed reduced Ki-67 expression and substantially decreased eEF2K protein by immunohistochemistry and Western blot.
- Western Blot
- Scratch/Wound-Healing Migration Assay
- Annexin V plus membrane-impermeant dye apoptosis staining
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Colony Formation (Clonogenic) Assay
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
- Kinase activity and phosphorylation assays
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- Apoptosis Solutions
- 3D Collagen/Hydrogel Matrix Migration Assay
- Protocol for Kinase activity and phosphorylation assays
- Soft Agar Colony Formation Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
Chemical Information
-
CAS. Nr. 3070364-13-2
-
Molecular Weight 757.83
-
Formel C39H47N7O9
-
SMILES
O=C(NCCCCCCCCNC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)CN4CCN(CCNC(C5=CC6=CC(O)=CC=C6OC5=O)=O)CC4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- PROTAC eEF2K degrader-2
- 3070364-13-2
- PROTACs
- CaMK
- Ligands for E3 Ligase
- Apoptosis
- PROTAC
- Calmodulin-dependent protein kinases
- Calmodulin-dependent kinases
- E3 ligase-recruiting Moiety
- CRBN
- apoptosis
- eEF2K
- epithelial-mesenchymal transition
- migration
- organoid
- polyubiquitination
- proliferation
- proteasomal degradation
- triple-negative breast cancer
- Inhibitor
- inhibitor
- inhibit